Abstract
Background
Hepatitis B virus-associated acute-on-chronic liver failure (HBV-ALCF) is a complicated syndrome with extremely high short-term mortality. The artificial liver support system (ALSS) may improve the liver function for patients with HBV-ACLF, but the data on its short-term outcomes are insufficient in China.
Methods
We recruited HBV-ACLF patients in this nationwide, multicenter, retrospective study. Patients with HBV-ACLF were diagnosed by the COSSH-ACLF criteria. Propensity score matching (PSM) analysis was used to generate compared pairs. The short-term (28/90 days) survival rates between the standard medical therapy (SMT) group and ALSS group were calculated using a Kaplan–Meier graph.
Result
In total, 790 patients with HBV-ACLF were included in this retrospective study; 412 patients received SMT only (SMT group), and 378 patients received SMT and ALSS treatment (ALSS group). PSM generated 310 pairs and eliminated the baseline differences between the two groups (p > 0.05 for all baseline variables). The probabilities of survival on day 28 were 65.2% (205/310) in the ALSS group and 59.0% (185/310) in the SMT group; on day 90, they were 51.0% (163/310) and 42.3% (136/310). The short-term (28/90 days) survival rates of the ALSS group were significantly higher than those of the SMT group (p=0.0452 and p=0.0187, respectively). Compared to receiving SMT alone, treatment with ALSS was associated with a significant reduction in serum bilirubin levels and the model for end-stage liver disease (MELD) scores at day 7 and day 28. Multivariate logistic regression analysis revealed that older age, high total bilirubin (T-Bil), low albumin, high ALT, high MELD scores, and high COSSH-ACLF grade were independent baseline factors associated with poor prognosis.
Conclusions
This retrospective study found that compared to SMT, the ALSS improved the short-term (28/90 days) survival rates and laboratory parameters in HBV-ACLF patients. The ALSS had a better therapeutic effect than SMT for patients with HBV-ACLF in China.
1. Introduction
Chronic hepatitis B (CHB) is a major public health challenge in China, with an estimated 78 million chronic carriers and 28 million patients with active hepatitis [1]. CHB is a significant risk factor that accounts for nearly 45% of cases of hepatocellular carcinoma (HCC) and 30% of cases of cirrhosis, causing nearly 1 million deaths each year worldwide [2, 3]. The high prevalence of CHB causes that hepatitis B virus (HBV) infection absolutely predominated in the etiologies of ACLF, accounting for 96.5% cases in China, while alcoholism is the most common etiologies of ACLF in western developed countries [4, 5].
HBV-related ACLF (HBV-ALCF) is a complicated syndrome with high short-term mortality (40–70% without liver transplantation) that develops in patients with HBV-related chronic liver disease [6, 7].
In past decades, a series of artificial liver support systems (ALSSs) have been applied in liver failure which aim to detoxify blood and compensate liver function for patients with liver failure. Molecular adsorbent recirculating system (MARS) [8, 9] and Prometheus [10, 11] are the most widely used ALSS. Li's artificial liver system (Li-ALS, the low-volume plasma exchange-centered ALSS) was designed by Professor Li's team since 1986 [12], which is mainly used in China. Some studies demonstrated that ALSSs could detoxify and ameliorate hepatic encephalopathy during acute liver failure (ALF) [11, 13, 14]. However, several large randomized trials noted that patients with ALF [15] or ACLF [16, 17], supported with ALSSs, did not show an increased short-term survival. A single-center study conducted in China reported that ALSS improved 90 days and 5 years outcomes of patients with HBV-ACLF [18].
In this study, we conducted a nationwide, multicenter, retrospective study to test whether ALSSs could improve the short-term (28/90 days) outcomes in patients with HBV-ALCF in China and identify predictive factors for the prognosis of these patients.
2. Methods
2.1. Patients
This is a retrospective cohort study where all data were fully anonymized before access. We recruited hospitalized patients with HBV-ACLF from 11 liver centers of Chinese University hospitals between January 2014 and May 2017. The following clinical data were collected: demographic data (age, sex, and body mass index), cirrhosis, laboratory measurements (HBV-DNA level, ALT, total bilirubin (T-Bil), INR, and creatinine), hepatic encephalopathy (HE), nucleos(t)ide analogs (NA), and survival time. The liver disease severity was assessed using the MELD scores and COSSH-ACLF grade (Chinese Group on the Study of Severe Hepatitis B-ACLF). The study was approved by the Ethics Committee of the First Affiliated Hospital, Zhejiang University School of Medicine.
2.2. Inclusion and Exclusion Criteria
The inclusion criteria were as follows:
Patients diagnosed with CHB [19] (HBV surface antigen-positive ≥6 months; serum HBV-DNA ≥20 000 IU/mL; a liver biopsy showing chronic hepatitis) and reached at least ACLF grade 1 diagnosed by the COSSH-ACLF criteria [6]:
ACLF grade 1: patients with kidney failure alone; patients with single liver failure (total bilirubin ≥12 mg/dL) with an international normalized ratio (INR) ≥1.5 and/or kidney dysfunction and/or HE grade I or II; patients with single type of organ failure of the coagulation, circulatory, or respiratory systems and/or kidney dysfunction and/or HE grade I or II; and patients with cerebral failure alone plus kidney dysfunction
ACLF grade 2: patients with failure of two organ systems
ACLF grade 3: patients with failure of 3 or more organ systems
The exclusion criteria were as follows:
Younger than 18 years or older than 80 years
Received a liver transplant
Human immunodeficiency virus infection
Diagnosed with HCC or another tumor
Dead within 3 days
Had a severe comorbidity that could affect survival
2.3. Therapies
According to the Diagnostic and Treatment Guideline for Liver Failure 2012 (Guideline (2012)) [20], the treatment for severe liver disease mainly consists of restoring and preserving vital organ function and slowing down the progression of multiple organ failure. The standard medical therapy (SMT) included a high-calorie diet; enteral nutrition is recommended; correction hypoproteinemia; correction water-electrolyte and acid-base balance; nucleoside analogs for HBV-DNA-positive patients; anti-infective therapy for infection; restricted protein diet; lactulose, ammonia drugs, and L-ornithine aspartate for HE; diuretics and tolvaptan for ascites; tubular active drugs; maintenance of arterial blood pressure and water restriction for hepatorenal syndrome; and oxygen therapy for hepatopulmonary syndrome.
According to the Guideline (2012), patients with early- or middle-stage liver failure were advised to receive ALSS treatment. For patients with early liver failure, PE was applied; for patients with metaphase hepatic failure, continuous blood purification (CBP) was applied; for patients with brain edema or renal failure or imbalance of water and electrolytes, CBP or plasma diafiltration (PDF) was applied; for patients with hyperbilirubinemia, plasma bilirubin absorption (PBA) was applied. The ALSS sessions were scheduled as follows: the ALSS was usually performed in 48 hours after diagnosis. ALSS treatment was performed daily on the first 2 or 3 days; future treatments were offered according to the patients' condition. Overall, 841 ALSS treatment sessions were applied in 310 patients (average of 2.7 sessions per patient, ranging from 1 to 8 sessions). 9 (2.9%) patients received PE (2–3 h/per session), and 301 (97.1%) patients received continuous renal replacement therapy (CRRT, 8 h/per session).
2.4. Statistical Analysis
Propensity score matching analysis was used to eliminate bias between the two groups. Propensity scores were computed using the following variables: age; sex; serum levels of HBV-DNA, ALT, T-Bil, and albumin; platelet count; white cell count; creatinine; INR; serum sodium; cirrhosis; HE; MELD score; and COSSH-ACLF grade. For propensity score matching, a nearest-neighbor 1 : 1 matching scheme was used. Categorical data were compared using the χ2 test or Fisher's exact test. Continuous variables were compared using the Mann–Whitney U test. The survival rate at 28 days and 90 days were calculated using a Kaplan–Meier graph. The difference in the survival rate was compared using a log-rank test. The relationship between baseline parameters and 28-day survival was studied using a multivariate logistic regression model. All statistical analyses were performed using IBM SPSS v. 24.0 for Windows (IBM Corp., Armonk, NY, USA). p values are two-tailed, and values less than 0.05 were considered statistically significant.
3. Results
3.1. Patient Characteristics
A total of 790 patients with HBV-ACLF were included in the study; 412 patients received standard treatment (SMT group) and 378 patients received ALSS treatment (ALSS group, Figure 1). Among them, 598 (85.3%) patients were male and 369 (52.5%) patients had no cirrhosis. Before matching, the baseline characteristics between two groups that differed significantly, such as ALT, T-Bil, and platelet count. Propensity score matching analysis generated 173 pairs, and the baseline characteristics of the pairs were balanced, with p > 0.05 for all baseline variables. After matching, the mean (SD) age of the patients in the SMT and ALSS groups was 45.4 (11.1) and 46.8 (11.3) for male, and the mean (SD) MELD scores were 25.1 (5.2) and 24.9 (5.6). In the SMT group, 118 (38.1%) patients had cirrhosis, and in the ALSS group, 133 (42.9%) patients had cirrhosis. All patients received NAs after diagnosis. In the SMT group, 155 patients received 100 mg of lamivudine (LAM) daily and 155 patients received 0.5 mg of entecavir (ETV) daily. In the ALSS group, 131 patients received 100 mg of LAM daily; 157 patients received 0.5 mg of ETV daily; 14 patients received 300 mg of tenofovir daily; and 8 patients received 600 mg of telbivudine daily. The characteristics of all patients are shown in Table 1.
Figure 1.
Flowchart of the patient selection process. HBV-ACLF, hepatitis B virus-related acute-on-chronic liver failure; LT, liver transplantation; STM, standard medical therapy; ALSS, artificial liver support system.
Table 1.
Clinical characteristics of the two groups studied at baseline.
| Characteristics | Entire cohort | Propensity score-matched cohort | ||||
|---|---|---|---|---|---|---|
| SMT (n = 412) | ALSS (n = 378) | p value | SMT (n = 310) | ALSS (n = 310) | p value | |
| Age (y) | 44.0 (10.6) | 46.9 (11.4) | 0.097 | 45.4 (11.1) | 46.8 (11.3) | 0.286 |
| Sex, male | 351 (85.2) | 337 (86.0) | 0.097 | 271 (87.4) | 274 (84.6) | 0.712 |
| HBV-DNA (log copies/mL) | 5.1 (1.6) | 5.1 (2.0) | 0.641 | 5.2 (1.1) | 5.1 (1.9) | 0.705 |
| Alanine transaminase level (IU/L) | 388.5 (277.4) | 341.1 (326.5) | 0.010 | 376.3 (239.8) | 360.4 (300.1) | 0.695 |
| Total bilirubin level (mg/dl) | 22.1 (7.4) | 24.4 (7.0) | 0.002 | 22.7 (7.4) | 23.9 (7.0) | 0.121 |
| Serum albumin level (g/L) | 33.1 (5.9) | 32.1 (6.3) | 0.027 | 33.1 (5.6) | 31.9 (5.4) | 0.149 |
| Platelet count (×105/mm3) (SD) | 107.3 (56.3) | 103.8 (48.1) | 0.015 | 105.3 (57.9) | 104.7 (45.8) | 0.893 |
| White cell count (×109/L) | 9.1 (21.3) | 7.9 (3.3) | 0.018 | 9.4 (24.1) | 7.6 (4.0) | 0.197 |
| Serum creatinine level (mg/dl) | 82.3 (44.3) | 76.5 (30.6) | 0.006 | 72.6 (23.7) | 68.5 (25.5) | 0.088 |
| International normalized ratio | 2.5 (0.9) | 2.5 (0.6) | 0.759 | 2.3 (0.8) | 2.4 (0.9) | 0.687 |
| Serum sodium (mEq/L) | 137.6 (4.5) | 136.0 (4.1) | <0.001 | 135.7 (4.9) | 136.4 (3.7) | 0.181 |
| Hepatic encephalopathy ≥ grade II | 9.5% (39/412) | 13.8% (52/378) | 0.059 | 10.3% (32/310) | 14.2% (44/378) | 0.142 |
| Cirrhosis | 158 (38.3) | 161 (42.6) | 0.225 | 118 (38.1) | 133 (42.9) | 0.220 |
| MELD score | 25.9 (5.2) | 24.8 (5.6) | 0.721 | 25.1 (5.2) | 24.9 (5.6) | 0.594 |
| COSSH-ACLF grade | 0.091 | 0.985 | ||||
| ACLF grade 1 | 226 (54.9) | 235 (62.2) | 207 (66.8) | 209 (67.4) | ||
| ACLF grade 2 | 174 (42.2) | 131 (34.7) | 94 (30.3) | 92 (29.7) | ||
| ACLF grade 3 | 12 (2.9) | 12 (3.2) | 9 (2.9) | 9 (2.9) | ||
| Nucleos(t)ide analogues | <0.001 | <0.001 | ||||
| Lamivudine | 205 | 167 | 155 | 131 | ||
| Entecavir | 207 | 182 | 155 | 157 | ||
| Tenofovir | 0 | 18 | 0 | 14 | ||
| Telbivudine | 0 | 11 | 0 | 8 | ||
Values are expressed as number and percentage or mean ± SD unless otherwise specified. SMT, standard medical therapy; ALSS, artificial liver support system; MELD, model for end-stage liver disease; COSSH-ACLF, Chinese Group on the Study of Severe Hepatitis B-ACLF.
3.2. Survival Rates
For all patients, the short-term (28/90 days) survival rates were 60.0% (474/790) and 45.8% (362/790). The 28-day survival rates were 65.2% (205/310) in the ALSS group and 59.0% (185/310) in the SMT group; the 90-day survival rates were 51.0% (163/310) and 42.3% (136/310), respectively. The short-term (28/90 days) mortality rate was significantly lower in the ALSS group than in the SMT group (p=0.0452; p=0.0187, Figures 2(a) and 2(b)).
Figure 2.
Short-term (28/90 days) survival curves for patients with HBV-ACLF. (a) 28-day survival curves for patients in the SMT and ALSS groups. (b) 90-day survival curves for patients in the SMT and ALSS groups. HBV-ACLF, hepatitis B virus-related acute-on-chronic liver failure; STM, standard medical therapy; ALSS, artificial liver support system.
In the SMT group, patients treated with entecavir had similar short-term survival rates than patients treated with lamivudine (p > 0.05). In the ALSS group, patients treated with entecavir had higher short-term (28/90 days) survival rates than patients treated with lamivudine (77.1%: 64.1%; 62.4%: 49.6%, p < 0.05, Table 2). The short-term (28/90 days) survival rates in the patients with noncirrhotic HBV-ACLF (63.6%/49.65%) and cirrhotic HBV-ACLF (61.8%/46.2%) were not significantly different.
Table 2.
Short-term (28/90 days) survival rates for patients treated with lamivudine vs entecavir or patients with noncirrhotic HBV-ACLF vs cirrhotic HBV-ACLF.
| Nucleos(t)ide analogues | 28-day survival rate | 90-day survival rate | ||||
|---|---|---|---|---|---|---|
| SMT | ALSS | Overall | SMT | ALSS | Overall | |
| Lamivudine | 61.3% (95/155) | 64.1% (84/131) | 62.6% (179/286) | 41.9% (65/155) | 49.6% (65/131) | 45.5 (130/286) |
| Entecavir | 58.1% (90/155) | 77.1% (121/157) | 67.6% (211/312) | 45.8% (71/155) | 62.4% (98/157) | 54.2% (169/312) |
| p value | 0.563 | 0.016 | 0.794 | 0.492 | 0.029 | 0.033 |
| Noncirrhotic HBV-ACLF | 60.4% (116/192) | 67.0% (120/179) | 63.6% (236/371) | 45.3% (87/192) | 54.2% (97/179) | 49.6% (184/371) |
| Cirrhotic HBV-ACLF | 58.5% (69/118) | 64.9% (85/131) | 61.8% (154/249) | 41.5% (49/118) | 50.4% (66/131) | 46.2% (115/249) |
| p value | 0.735 | 0.692 | 0.656 | 0.514 | 0.507 | 0.405 |
The 28-day survival rates of patients with ACLF grades 1–3 were 72.5%, 37.2%, and 0 in the SMT group and 78.5%, 43.5%, and 11.1% in the ALSS group. The 90-day survival rates of patients with ACLF grades 1–3 were 55.6%, 22.3%, and 0 in the SMT group and 65.1%, 29.3%, and 0% in the ALSS group (Table 3).
Table 3.
Short-term survival rates for patients in different COSSH-ACLF grades.
| COSSH-ACLF | Prevalence | 28-day survival rate | 90-day survival rate |
|---|---|---|---|
| Total (n = 790) | 60.0% (474/790) | 45.8% (362/790) | |
| ACLF grade 1 | 58.4% (461/790) | 76.1% (351/461) | 61.2% (282/461) |
| ACLF grade 2 | 38.6% (305/790) | 40.0% (122/305) | 26.2% (80/305) |
| ACLF grade 3 | 3.0% (24/790) | 4.2% (1/24) | 0 (0/24) |
| SMT (n = 310) | 59.0% (185/310) | 42.3% (136/310) | |
| ACLF grade 1 | 66.8% (207/310) | 72.5% (150/207) | 55.6% (115/207) |
| ACLF grade 2 | 30.3% (94/310) | 37.2% (35/94) | 22.3% (21/94) |
| ACLF grade 3 | 2.9% (9/310) | 0 (0/9) | 0 (0/9) |
| ALSS (n = 310) | 65.2% (205/310) | 51.0% (163/310) | |
| ACLF grade 1 | 67.4% (209/310) | 78.5% (164/209) | 65.1% (136/209) |
| ACLF grade 2 | 29.7% (92/310) | 43.5% (40/92) | 29.3% (27/92) |
| ACLF grade 3 | 2.9% (9/310) | 11.1% (1/9) | 0 (0/9) |
SMT, standard medical therapy; ALSS, artificial liver support system.
3.3. Changes in Laboratory Parameters at Day 7 and Day 28
The effect of treatment on laboratory parameters at day 7 and day 28 is shown in Tables 4 and 5, respectively. Compared with the SMT treated alone group, treatment with ALSS was associated with a significant reduction in serum T-Bil levels and MELD scores at both day 7 and day 28; however, the serum creatinine only decreased at day 7. The remaining analyzed parameters showed no significant difference between the two groups.
Table 4.
Effects of treatment on laboratory parameters at day 7.
| Parameter | SMT (n = 272) | ALSS (n = 392) | p value |
|---|---|---|---|
| Serum bilirubin (mg/dl) | |||
| Baseline | 22.8 (7.3) | 23.6 (7.0) | |
| Day 7 | 23.9 (7.5) | 22.2 (6.8) | |
| Change from baseline | 1.1 (7.2) | −1.4 (4.7) | 0.008 |
| Serum albumin (g/L) | |||
| Baseline | 33.6 (5.4) | 32.1 (5.3) | |
| Day 7 | 33.8 (7.7) | 34.1 (7.3) | |
| Change from baseline | 0.2 (4.5) | 2.0 (17.3) | 0.067 |
| Baseline international normalized ratio | |||
| Baseline | 2.3 (0.8) | 2.4 (0.9) | |
| Day 7 | 2.2 (0.8) | 2.2 (0.8) | |
| Change from baseline | −0.1 (0.50) | −0.2 (0.92) | 0.064 |
| Serum creatinine (μmol/L) | |||
| Baseline | 72.6 (23.7) | 68.5 (25.5) | |
| Day 7 | 75.9 (28.5) | 66.2 (24.8) | |
| Change from baseline | 3.3 (25.2) | −2.3 (17.9) | 0.043 |
| Alanine transaminase level (IU/L) | |||
| Baseline | 371.8 (237.1) | 360.4 (300.1) | |
| Day 7 | 138.4 (137.1) | 159.7 (196.7) | |
| Change from baseline | −233.4 (293.7) | −200.7 (241.8) | 0.071 |
| MELD score | |||
| Baseline | 25.2 (5.1) | 25.0 (5.6) | |
| Day 7 | 25.1 (4.7) | 24.3 (5.8) | |
| Change from baseline | −0.1 (3.4) | −0.7 (6.2) | 0.036 |
SMT, standard medical therapy; ALSS, artificial liver support system; MLED, model for end-stage liver disease.
Table 5.
Effects of treatment on laboratory parameters at day 28.
| Parameter | SMT (n = 185) | ALSS (n = 205) | p value |
|---|---|---|---|
| Serum bilirubin (mg/dl) | |||
| Baseline | 22.1 (7.1) | 23.2 (6.8) | <0.001 |
| Day 28 | 15.2 (10.1) | 22.8 (10.8) | |
| Change from baseline | −4.4 (9.5) | −6.9 (9.5) | |
| Serum albumin (g/L) | |||
| Baseline | 33.6 (5.4) | 32.1 (5.3) | |
| Day 28 | 33.8 (7.7) | 34.1 (7.3) | |
| Change from baseline | 0.2 (4.5) | 2.0 (17.3) | 0.067 |
| Baseline international normalized ratio | |||
| Baseline | 2.3 (0.6) | 2.3 (0.6) | |
| Day 28 | 1.7 (0.7) | 1.7 (0.7) | |
| Change from baseline | −0.5 (0.7) | −0.5 (0.7) | 0.975 |
| Serum creatinine (μmol/L) | |||
| Baseline | 73.2 (22.7) | 70.9 (22.8) | |
| Day 28 | 72.4 (34.5) | 70.8 (25.9) | |
| Change from baseline | −0.8 (34.8) | −0.1 (23.4) | 0.088 |
| ALT (IU/L) | |||
| Baseline | 356.2 (242.5) | 367.3 (287.4) | |
| Day 7 | 60.8 (89.7) | 44.9 (26.7) | |
| Change from baseline | −295.4 (293.7) | −322.4 (241.8) | 0.085 |
| MELD score | |||
| Baseline | 25.2 (4.2) | 25.4 (4.8) | |
| Day 28 | 17.7 (9.5) | 16.8 (7.8) | |
| Change from baseline | −7.5 (8.2) | −8.6 (6.4) | 0.042 |
SMT, standard medical therapy; ALSS, artificial liver support system; MLED, model for end-stage liver disease.
3.4. Risk Factors on 28-Day Survival
Using multivariate logistic regression analysis, the independent baseline risk factors for 28-day survival were identified as age, T-Bil, low albumin, ALT, MELD score, and COSSH-ACLF grade (Table 6). Cirrhosis, INR, serum creatinine, and platelet count were not independent predictors of 28-day survival.
Table 6.
Multivariate logistic regression model investigating independent risk factors on 28-day survival.
| Variable | Reference | OR (CI 95 %) | p value |
|---|---|---|---|
| Age | Per year | 1.017 (1.002–1.033) | 0.022 |
| Total bilirubin | Per unit increase | 1.062 (1.035–1.088) | <0.001 |
| Alanine transaminase | Per unit increase | 1.001 (1.000–1.0001) | 0.001 |
| Albumin | Per unit decline | 1.053 (1.011–1.074) | 0.009 |
| MELD score | Per point increase | 1.059 (1.011–1.109) | 0.015 |
| COSSH-ACLF grade | Per rank increase | 2.683 (1.792–4.017) | <0.001 |
MLED, model for end-stage liver disease; COSSH-ACLF, Chinese Group on the Study of Severe Hepatitis B-ACLF.
4. Discussion
HBV-ACLF is observed in populations with HBV-related chronic liver disease. Liver transplantation is the most effective therapy for patients with liver failure; however, less than 30% of patients have access to transplantation because of donor shortages and the extremely poor prognosis of HBV-ACLF [21]. Although NA treatment could effectively decrease the 3-month mortality for patients with HBV-ACLF, NAs are only valid in patients with MELD scores less than 30 [22, 23]. In addition, mutations resistant to NAs are frequent precipitating events of HBV-ACLF, which is related to high mortality [24]. The development of ACLF includes the accumulation of various metabolites and toxins that vary in size, distribution volume, lipophilicity, and protein-binding abilities [25, 26]. Most ALSSs are capable of correcting the hemato-microenvironment, such as detoxification, synthesis, immune regulation, and reducing mortality in patients with ACLF, when compared with SMT [27]. Therefore, ALSS has been recommended as an important method to treat ACLF.
HBV-ACLF is a special type of ACLF and is the most frequent ACLF in China. This large, multicenter, nationwide, historical retrospective study showed that treatment with ALSS in patients with HBV-ACLF remarkably improved their short-term (28/90 days) survival rates compared with those receiving SMT only. The results indicated that ALSS is effective at removing the toxic substances from plasma that accumulate in patients with HBV-ACLF (confirmed by the significant decreased in T-Bil), correcting coagulopathy (confirmed by the INR decline), and alleviating renal failure (confirmed by the creatinine decline). The functions of synthesis and immune regulation have been well established in pigs with ALF, although further clinical studies are needed.
The ALSS performed in this study innovatively used plasma separators with an aperture of about 1/10 (membrane pore size = 0.03 μm) of that of a normal plasma separator for direct PE, which could remove toxic substances effectively for patients with liver failure, retain important plasma components, and reduce the plasma dosage [28]. Although high-volume plasma (HVP, approximately 8 L) exchange has a beneficial therapeutic effect on patients with ALF [26, 29], it is usually performed over more than two sessions for patients with ACLF, which results in a shortage of fresh plasma. Moreover, the HVP removes almost all elements of plasma; part of them are beneficial substances (such as hepatic growth factor) for liver regeneration [30]. In this study, the ALSS using lower-volume plasma (LVP) exchange in which the total volume of exchanged fresh plasma is approximately 1500 mL [12]. The LVP is usually the first step of the ALSS, and subsequent adsorption and hemofiltration circulation are conducted through autologous plasma derived from waste plasma. The waste plasma is purified, which avoids wasting massive plasma and reduces the loss of essential substances. However, whether low-volume PE provides better results compared with high-volume PE remains unclear.
Selection of suitable inclusion criteria is crucial to evaluate the efficacy of ALSS for patients with HBV-ACLF. HBV-ACLF is an extremely special type of ACLF with some distinctive characteristics. Patients with HBV-ACLF have poorer prognosis than patients with non-HBV-ACLF (the 28/90 days mortality rates were 60.2% vs 52.1% and 73.9% vs 69.7%) [6]. Patients with HBV-ACLF have a higher incidence of liver and coagulation failure [31, 32], whereas kidney failure and cerebral failure are the most common types of organ failure in patients with non-HBV-ACLF. Reactivation of HBV, an acute hepatic insult, is the leading cause of HBV-ACLF in the Asian region [33–36]. The European Association for the Study of the Liver (EASL) criteria and the American Association for the Study of Liver Diseases (AASLD) criteria are the major criteria for ACLF in patients from Europe and North America, where alcoholic liver disease is the major etiology [7, 37]. These criteria may not apply to China, where hepatitis B virus infection is the major etiology in China. The COSSH criteria were established based on a large Chinese HBV-ACLF group which is in accordance with our study group. Therefore, we chose the COSSH criteria as the inclusion criteria.
A previous study showed that the first leading cause of HBV-ACLF was spontaneous severe acute exacerbation of CHB (62.5%) and the second leading cause was alcohol (15.4%) in Asia [5]. The oral NA therapy effectively suppresses viral DNA and prevents the progression of liver inflammation; therefore, rapid initiation of oral NA treatment in patients with HBV-ACLF is recommended widely [38, 39]. LAM and ETV are both widely used in China, though LAM has less potency and has higher resistance (LAM: 70%; ETV: 1.2%) than ETV [39].
This study revealed that compared with LAM, ETV did not improve the short-term survival rates in HBV-ACLF, neither in the SMT group nor ALSS group. These results were similar to a largest meta-analysis, which demonstrated a comparable short-term mortality (within 4 months) of LAM and ETV; however, ETV revealed a more favorable long-term (beyond 4 months) outcome than LAM in patients with HBV-ACLF [40]. The results of multivariate logistic regression showed that cirrhosis is not a risk-independent predictor of 28-day survival. We also found a similarly short-term survival rate in patients with both cirrhotic HBV-ACLF (61.8%/46.2%) and noncirrhotic HBV-ACLF (63.6%/49.65%). However, this result was not in line with that of Wu's study, which indicated that cirrhosis patients had superior 28-day survival rate than noncirrhosis patients (47.9%: 39.8%, p < 0.05) [6]. The contradictory outcomes might result from small population samples of this study. In previous studies, T-Bil and platelet levels were found as independent risk factors of mortality among HBV-ACLF patients; however, in our study, the significant difference was only found in single-factor logistic regression analysis.
In conclusion, among patients with HBV-ACLF in China, ALSS has better therapeutic effect than SMT. Though the treatment for HBV-ACLF haas improved over the past three decades the short-term mortality of ACLF remains high. Therefore, more effective therapeutic methods should be investigated.
Acknowledgments
This work was supported by the Science & Technology Key Program of Zhejiang China (#2017C03051).
Data Availability
All relevant data are within the paper and its supporting information file.
Ethical Approval
The study was reviewed and approved by the ethics committee of the First Affiliated Hospital, College of Medicine, Zhejiang University.
Conflicts of Interest
The authors have declared that there are no conflicts of interest.
Authors' Contributions
Li LJ and Xiao LL designed the research. Xiao LL, Xu XW, Wu XX, Huang KZ, and Zhang LJ performed the research. Xiao LL and Zhao YL analyzed the data. All authors wrote the paper, had access to the study data, and have reviewed and approved the final manuscript.
References
- 1.Zhang S., Wang F., Zhang Z. Current advances in the elimination of hepatitis B in China by 2030. Frontiers of Medicine. 2017;11(4):490–501. doi: 10.1007/s11684-017-0598-4. [DOI] [PubMed] [Google Scholar]
- 2.Vos T., Abajobir A. A., Abate K. H. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the global burden of disease study 2016. The Lancet. 2017;390(10100):1211–1259. doi: 10.1016/S0140-6736(17)32154-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Nayagam S., Thursz M., Sicuri E., et al. Requirements for global elimination of hepatitis B: a modelling study. The Lancet Infectious Diseases. 2016;16(12):1399–1408. doi: 10.1016/s1473-3099(16)30204-3. [DOI] [PubMed] [Google Scholar]
- 4.Wang F.-S., Fan J.-G., Zhang Z., Gao B., Wang H.-Y. The global burden of liver disease: the major impact of China. Hepatology. 2014;60(6):2099–2108. doi: 10.1002/hep.27406. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Xie G.-J., Zhang H.-Y., Chen Q., et al. Changing etiologies and outcome of liver failure in Southwest China. Virology Journal. 2016;13(1):p. 89. doi: 10.1186/s12985-016-0536-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Wu T., Li J., Shao L. Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure. Hepatology. 2017;67(12):2181–2191. doi: 10.1136/gutjnl-2017-314641. [DOI] [PubMed] [Google Scholar]
- 7.Moreau R., Jalan R., Gines P., et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013;144(7):1426.e9–1437.e9. doi: 10.1053/j.gastro.2013.02.042. [DOI] [PubMed] [Google Scholar]
- 8.Stange J., Mitzner, Risler, et al. Molecular adsorbent recycling system (MARS): clinical results of a new membrane-based blood purification system for bioartificial liver support. Artificial Organs. 1999;23(4):319–330. doi: 10.1046/j.1525-1594.1999.06122.x. [DOI] [PubMed] [Google Scholar]
- 9.Kapoor D., Williams R., Jalan R. MARS: a new treatment for hepatorenal failure. Gastroenterology. 2000;119(6):1799–1800. doi: 10.1016/s0016-5085(00)70033-3. [DOI] [PubMed] [Google Scholar]
- 10.Rifai K., Ernst T., Kretschmer U., et al. Prometheus®—a new extracorporeal system for the treatment of liver failure. Journal of Hepatology. 2003;39(6):984–990. doi: 10.1016/s0168-8278(03)00468-9. [DOI] [PubMed] [Google Scholar]
- 11.Evenepoel P., Laleman W., Wilmer A., et al. Detoxifying capacity and kinetics of prometheus®—a new extracorporeal system for the treatment of liver failure. Blood Purification. 2005;23(5):349–358. doi: 10.1159/000086885. [DOI] [PubMed] [Google Scholar]
- 12.Li L. J. Artificial Liver. Hangzhou, China: Zhejiang University Press; 2012. [Google Scholar]
- 13.Banares R., Nevens F., Larsen F. S., et al. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology. 2013;57(3):1153–1162. doi: 10.1002/hep.26185. [DOI] [PubMed] [Google Scholar]
- 14.Zhou N., Li J., Zhang Y., et al. Efficacy of coupled low-volume plasma exchange with plasma filtration adsorption in treating pigs with acute liver failure: a randomised study. Journal of Hepatology. 2015;63(2):378–387. doi: 10.1016/j.jhep.2015.03.018. [DOI] [PubMed] [Google Scholar]
- 15.Saliba F., Camus C., Durand F., et al. Predictive factors of transplant free survival in patients with fulminant and subfulminant liver failure: results from a randomized controlled multicenter trial. Journal of Hepatology. 2009;50:S89–S90. doi: 10.1016/s0168-8278(09)60222-1. [DOI] [Google Scholar]
- 16.Inderbitzin D., Muggli B., Ringger A., et al. Molecular absorbent recirculating system for the treatment of acute liver failure in surgical patients. Journal of Gastrointestinal Surgery. 2005;9(8):1155–1162. doi: 10.1016/j.gassur.2005.07.026. [DOI] [PubMed] [Google Scholar]
- 17.Kribben A., Gerken G., Haag S., et al. Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure. Gastroenterology. 2012;142(4):782.e3–789.e3. doi: 10.1053/j.gastro.2011.12.056. [DOI] [PubMed] [Google Scholar]
- 18.Qin G., Shao J. G., Wang B., et al. Artificial liver support system improves short- and long-term outcomes of patients with HBV-associated acute-on-chronic liver failure: a single-center experience. Medicine (Baltimore) 2014;93(28):p. e338. doi: 10.1097/md.0000000000000338. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Lok A. S., McMahon B. J. Chronic hepatitis B: update 2009. Hepatology. 2009;50(3):661–662. doi: 10.1002/hep.23190. [DOI] [PubMed] [Google Scholar]
- 20.Chinese Medical Association. Diagnostic and treatment guideline for liver failure. Chinese Journal of Infectious Diseases. 2013;31(3):129–137. [Google Scholar]
- 21.Kim W. R., Smith J. M., Skeans M. A., et al. OPTN/SRTR 2012 annual data report: liver. American Journal of Transplantation. 2014;1:69–96. doi: 10.1111/ajt.12581. [DOI] [PubMed] [Google Scholar]
- 22.Chen T., He Y., Liu X., et al. Nucleoside analogues improve the short-term and long-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure. Clinical and Experimental Medicine. 2012;12(3):159–164. doi: 10.1007/s10238-011-0160-7. [DOI] [PubMed] [Google Scholar]
- 23.Sun L.-J., Yu J.-W., Zhao Y.-H., Kang P., Li S.-C. Influential factors of prognosis in lamivudine treatment for patients with acute-on-chronic hepatitis B liver failure. Journal of Gastroenterology and Hepatology. 2010;25(3):583–590. doi: 10.1111/j.1440-1746.2009.06089.x. [DOI] [PubMed] [Google Scholar]
- 24.Zoulim F., Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology. 2009;137(5):1593–1608. doi: 10.1053/j.gastro.2009.08.063. [DOI] [PubMed] [Google Scholar]
- 25.Bernal W., Wendon J. Acute liver failure. The New England Journal of Medicine. 2013;369(26):2525–2534. doi: 10.1056/nejmra1208937. [DOI] [PubMed] [Google Scholar]
- 26.Lee W. M., Stravitz R. T., Larson A. M. Introduction to the revised American association for the study of liver diseases position paper on acute liver failure 2011. Hepatology. 2012;55(3):965–967. doi: 10.1002/hep.25551. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Kjaergard L. L., Liu J., Nielsen B., Gluud C. Artificial and bioartificial support systems for acute and acute-on-chronic liver failure: a systematic review. JAMA. 2003;289(2):217–222. doi: 10.1001/jama.289.2.217. [DOI] [PubMed] [Google Scholar]
- 28.Li L. J., Liu X. L., Xu X. W., et al. Comparison of plasma exchange with different membrane pore sizes in the treatment of severe viral hepatitis. Therapeutic Apheresis and Dialysis. 2005;9(5):396–401. doi: 10.1111/j.1744-9987.2005.00277.x. [DOI] [PubMed] [Google Scholar]
- 29.Kondrup J., Almdal T., Vilstrup H., Tygstrup N. High volume plasma exchange in fulminant hepatic failure. The International Journal of Artificial Organs. 1992;15(11):669–676. doi: 10.1177/039139889201501110. [DOI] [PubMed] [Google Scholar]
- 30.Eguchi S., Sugiyama N., Kawazoe Y., et al. Total blood exchange suppresses the early stage of liver regeneration following partial hepatectomy in rats. Journal of Artificial Organs. 1998;22(10):847–853. doi: 10.1046/j.1525-1594.1998.06166.x. [DOI] [PubMed] [Google Scholar]
- 31.Li H., Chen L. Y., Zhang N. N., et al. Characteristics, diagnosis and prognosis of acute-on-chronic liver failure in cirrhosis associated to hepatitis B. Scientific Reports. 2016;6(1) doi: 10.1038/srep25487. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Shi Y., Yang Y., Hu Y., et al. Acute-on-chronic liver failure precipitated by hepatic injury is distinct from that precipitated by extrahepatic insults. Hepatology. 2015;62(1):232–242. doi: 10.1002/hep.27795. [DOI] [PubMed] [Google Scholar]
- 33.Lim S. G., Wai C. T., Rajnakova A., Kajiji T., Guan R. Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B. Gut. 2002;51:597–599. doi: 10.1136/gut.51.4.597. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Huang M., Huang L. Reactivation of hepatitis C viral infection after treatment with infliximab. Journal of Clinical Gastroenterology. 2014;48(2):189–190. doi: 10.1097/mcg.0000000000000001. [DOI] [PubMed] [Google Scholar]
- 35.Sagnelli E., Pisaturo M., Stanzione M., et al. Clinical presentation, outcome, and response to therapy among patients with acute exacerbation of chronic hepatitis C. Clinical Gastroenterology and Hepatology. 2013;11(9):1174.e11–1180.e11. doi: 10.1016/j.cgh.2013.03.025. [DOI] [PubMed] [Google Scholar]
- 36.Magalhães R. K., Ferreira D., Salgado M., Pedroto I. Hepatitis B virus reactivation after chemotherapy in an HIV-positive patient. Journal of Clinical Gastroenterology. 2013;47(6):565–566. doi: 10.1097/mcg.0b013e318282971e. [DOI] [PubMed] [Google Scholar]
- 37.Sarin S. K., Kedarisetty C. K., Abbas Z., et al. Acute-on-chronic liver failure: consensus recommendations of the asian pacific association for the study of the liver (APASL) 2014. Hepatology International. 2014;8(4):453–471. doi: 10.1007/s12072-014-9580-2. [DOI] [PubMed] [Google Scholar]
- 38.Liaw Y. F., Kao J. H., Piratvisuth T., et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatology International. 2012;6:531–561. doi: 10.1007/s12072-012-9365-4. [DOI] [PubMed] [Google Scholar]
- 39.European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. Journal of Hepatology. 2012;57(1):167–185. doi: 10.1016/j.jhep.2012.02.010. [DOI] [PubMed] [Google Scholar]
- 40.Huang K.-W., Tam K.-W., Luo J.-C., Kuan Y.-C. Efficacy and safety of lamivudine versus entecavir for treating chronic hepatitis B virus-related acute exacerbation and acute-on-chronic liver failure: a systematic review and meta-analysis. Journal of Clinical Gastroenterology. 2017;51(6):539–547. doi: 10.1097/mcg.0000000000000675. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
All relevant data are within the paper and its supporting information file.